People · Operator
Named in public records as an officer, director or promoter · active 2011–2024 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Aravive, Inc. | — | Biotechnology | Series C | $156.1M | $702.9M | 2014 |
| NEXTWAVE PHARMACEUTICALS Inc | — | Pharmaceuticals | Series B | $27.2M | $925.9M | 2011 |
| Cessation Therapeutics, Inc. | — | Biotechnology | Series A | $6.8M | $5.9M | 2022 |
Jay Shepard at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jay Shepard on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Kevin Johnson | 1 | 12 |
| Srinivas Akkaraju | 1 | 10 |
| Anthony Sun | 1 | 8 |
| ANAND MEHRA | 1 | 7 |
| MICHAEL DYBBS | 1 | 5 |
| Shahzad Malik | 1 | 4 |
| Dayton Misfeldt | 1 | 4 |
| Francesco De Rubertis | 1 | 4 |
| JEFFREY CLELAND | 1 | 4 |
| Sharon Tetlow | 1 | 4 |
| Steve Elms | 1 | 4 |
| David Genecov | 1 | 4 |
| Michael W. Rogers | 1 | 4 |
| Linda Ara | 1 | 3 |
| Daniel Fine | 1 | 3 |
| John Harkey | 1 | 3 |
| Gaurav Aggarwal | 1 | 3 |
| Joshua Brumm | 1 | 2 |
| Frank Kung | 1 | 2 |
| Volker Schellenberger | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.